According to this recent study, melanoma incidence has declined in some younger age groups in Australia, including among people with high risk
ancestry. Authors conclude that social and behavioural changes over the same period that lead to lower levels of ultraviolet radiation exposure probably contributed to these changes.
This recent study aimed to determine adherence to personal risk-tailored melanoma skin check schedules and explore reasons influencing adherence. The study concludes that there was moderate adherence, and that further adherence may be gained by incorporating strategies to identify and assist patients with high levels of anxiety and supporting clinicians to communicate risk-based recommendations with patients.
According to this recent study, in patients with stage III melanoma, adjuvant lymph-node field radiotherapy combined with immunotherapy seems to be associated with longer disease-free survival, with acceptable tolerance. Results need to be confirmed by long-term and prospective studies.
Multiple types of extracellular vesicles (EVs) have emerged as promising platforms for melanoma vaccination. This review focuses on the construction strategies for EV vaccines from various sources, their effects, and immunological mechanisms in treating melanoma, as well as the shortcomings and future perspectives in this field.
According to this recent study, circulating interleukin-8 (IL-8) and osteopontin appear useful biomarkers to refine prognosis evaluation of patients with advanced melanoma undergoing targeted therapy.
Findings of this recent cohort study of patients with advanced melanoma treated with immune checkpoint inhibitors in clinical practice showed that their survival reached a plateau, comparable with patients participating in clinical trials. Authors of the study conclude that these findings can be used in daily clinical practice to guide long-term surveillance strategies and inform both physicians and patients regarding long-term treatment outcomes.
According to this recent study, the establishment of a personalised screening programme is complex, but results of the reviewed studies indicate that it is feasible, can improve participation rates, and screening outcomes. The study concludes that while the review primarily examined screening programmes for cancers other than melanoma, the insights can be used to inform the development of a personalised melanoma screening strategy.
According to this recent study, adjuvant pembrolizumab did not have a significant impact on long-term health-related quality of life (HRQOL) compared with placebo in patients with resected stage III melanoma. These findings, together with earlier results on efficacy and HRQOL, support the use of pembrolizumab in this setting.
Survival outcomes after postrecurrence therapy were investigated in the CheckMate 238 trial, during which patients with resected melanoma received adjuvant treatment with nivolumab or ipilimumab. This recent study concludes that postrecurrence survival was longer for patients who recurred >12 months. Patients on nivolumab who recurred early benefitted from subsequent systemic therapy but had better survival with ipilimumab-based regimens or targeted therapy compared with anti–PD-1 monotherapy.
General Practitioners (GPs) are the first interaction for most patients with skin cancer concerns and are well placed to provide information regarding primary and secondary skin cancer prevention. This article aims to discuss primary and secondary prevention of skin cancer in Australia.